+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dermatological Non-Steroidal Anti-Inflammatory Drugs Market by Route of Administration (Oral, Parenteral, Topical), Product Type (Injectable, Oral Capsule, Oral Liquid), Distribution Channel, End User, Indication - Global Forecast 2025-2030- Product Image
Dermatological Non-Steroidal Anti-Inflammatory Drugs Market by Route of Administration (Oral, Parenteral, Topical), Product Type (Injectable, Oral Capsule, Oral Liquid), Distribution Channel, End User, Indication - Global Forecast 2025-2030- Product Image
Sale

Dermatological Non-Steroidal Anti-Inflammatory Drugs Market by Route of Administration (Oral, Parenteral, Topical), Product Type (Injectable, Oral Capsule, Oral Liquid), Distribution Channel, End User, Indication - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6081793
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Dermatological non-steroidal anti-inflammatory drugs have emerged as indispensable tools in the management of a diverse array of skin and musculoskeletal conditions. Their mechanism of action, which involves the modulation of inflammatory pathways without the adverse effects commonly associated with corticosteroids, has positioned these agents at the forefront of therapeutic regimens. Clinicians increasingly rely on topical NSAID formulations to address localized pain and inflammation, while systemic oral and parenteral options continue to serve patients with more extensive inflammatory disorders.

As patient awareness of safety profiles and efficacy grows, the demand for innovative delivery systems has intensified. This convergence of clinical need and consumer expectation underscores the transformative potential of dermatological NSAIDs. Stakeholders across the healthcare continuum must now navigate a landscape shaped by evolving regulatory frameworks, technological breakthroughs in formulation, and shifting patterns of healthcare consumption, all of which reinforce the critical importance of understanding market fundamentals before charting strategic initiatives.

Exploring transformative shifts in treatment paradigms regulatory landscapes and patient expectations shaping future dermatological NSAID applications

Recent years have witnessed a pronounced shift in how dermatological NSAIDs are developed, regulated, and adopted in clinical practice. Regulators worldwide have instituted more rigorous safety assessments, prompting manufacturers to invest heavily in advanced formulation technologies. Microemulsion gels, bioadhesive patches, and nanoparticle-enhanced ointments exemplify the drive toward enhanced bioavailability and targeted delivery, enabling clinicians to achieve optimal therapeutic outcomes with minimal systemic exposure.

Simultaneously, patient expectations have evolved, with increased demand for personalized treatment regimens that integrate seamlessly into daily life. Digital health platforms now empower individuals to track treatment adherence and symptom progression, informing real-time adjustments to therapy. These technological innovations, coupled with collaborative efforts between pharmaceutical companies and academic research centers, have led to a new era of dermatological NSAIDs that blend evidence-based formulation science with patient-centric care models.

Assessing the cascading effects of new US tariff implementations on supply chain dynamics raw material sourcing and pricing pressures in dermatological NSAID markets

The introduction of revised United States tariffs slated for 2025 has created a ripple effect across global supply chains for active pharmaceutical ingredients and excipients used in dermatological NSAID products. Manufacturers are reassessing sourcing strategies, with an emphasis on diversifying supplier bases and exploring regional procurement alternatives to mitigate cost pressures. This recalibration has also prompted greater collaboration between raw material producers and formulation specialists to secure supply continuity while optimizing production costs.

Moreover, import duty adjustments have driven a reassessment of pricing strategies, compelling companies to seek efficiencies in manufacturing processes and distribution logistics. These developments have underscored the importance of agility in responding to regulatory changes. Firms that proactively engage with customs authorities, negotiate long-term supplier contracts, and adapt their production footprints are better positioned to maintain competitive pricing and sustain revenue streams in the face of fiscal headwinds.

Unveiling key segmentation insights through routes of administration product types distribution channels end users and therapeutic indications in dermatological NSAIDs

A nuanced understanding of market segmentation reveals vital pathways for tailored product development and strategic positioning. Analysis by route of administration highlights that systemic oral therapies-encompassing capsule, liquid, and tablet formats-continue to address widespread inflammatory conditions, while parenteral options such as infusion and injection serve acute care settings with immediate anti-inflammatory requirements. Topical therapies have diversified to include creams, gels, ointments, patches, and sprays, each engineered for distinct release profiles and patient preferences.

Product type segmentation further illuminates specific innovation hotspots. Injectable formulations have advanced through refined excipient matrices, while oral capsules and liquids emphasize enhanced solubility and patient tolerability. Topical creams are now offered in high, medium, and low concentration variants to match severity levels, just as gels are available in gradations ranging from less than one percent to over two percent concentration. Distribution channel insights underscore the importance of hospital pharmacy relationships, growing online pharmacy adoption driven by e-commerce convenience, and enduring retail pharmacy networks that provide patient access and counseling. End-user segmentation points to clinics and hospital outpatient departments as primary demand centers for acute interventions, while home care settings increasingly leverage self-administrable topical and oral therapies for chronic conditions. Finally, indication-based analysis demonstrates that dermatological conditions remain the core focus, complemented by applications in musculoskeletal disorders, osteoarthritis, rheumatoid arthritis, and soft tissue injuries, each presenting unique formulation and delivery challenges.

Analyzing regional market performances across Americas Europe Middle East Africa and Asia-Pacific for dermatological non-steroidal anti-inflammatory products

Regional performance trends illustrate diverse market trajectories shaped by regulatory environments, healthcare infrastructure maturity, and demographic trends. In the Americas, a well-established pharmaceutical ecosystem and strong reimbursement frameworks support rapid adoption of advanced topical and systemic NSAID therapies. Leading players leverage robust clinical trial networks and favorable intellectual property protections to introduce cutting-edge formulations that address both formal healthcare settings and direct-to-consumer channels.

The Europe, Middle East, and Africa region presents a heterogeneous landscape in which regulatory harmonization efforts coexist with localized approval processes. Western Europe exhibits high uptake of next-generation formulations, whereas emerging markets in the Middle East and Africa experience gradual expansion driven by partnerships between multinational firms and regional distributors. This dual-speed environment underscores the need for adaptive regulatory strategies and regional alliances to navigate diverse market access pathways.

In Asia-Pacific, rapid urbanization and growing healthcare expenditure have fueled demand for both prescription and over-the-counter NSAID products. Innovative delivery formats, such as transdermal patches and metered-dose sprays, resonate in markets with high consumer health awareness. Local manufacturers and contract development organizations collaborate to accelerate product registration, capitalizing on streamlined approval mechanisms and government incentives for domestic production.

Highlighting major corporate players innovations strategic alliances and competitive positioning driving advancements in dermatological non-steroidal anti-inflammatory therapeutics

Leading companies in the dermatological NSAID arena exhibit a clear focus on pipeline diversification, strategic partnerships, and intellectual property development. Major pharmaceutical corporations have established dedicated research hubs to explore next-generation drug delivery technologies, forging collaborations with biotech innovators specializing in nanocarrier systems and bioresponsive polymers. These alliances enable accelerated proof-of-concept studies and de-risked progression from lab to clinic.

Meanwhile, mid-sized specialty firms are carving out niches through targeted acquisitions and licensing agreements, often securing rights to novel topical formulations or exclusive distribution partnerships in under-penetrated regions. They invest in life-cycle management programs, optimizing existing product lines through enhanced safety profiles and patient adherence initiatives. As competitive dynamics intensify, companies also invest in digital health platforms that integrate therapeutic monitoring with patient support services, reinforcing brand loyalty and real-world evidence generation.

Actionable recommendations for industry leaders to optimize portfolios streamline regulatory compliance and enhance market responsiveness in dermatological NSAID sectors

Industry leaders should prioritize a multifaceted approach that aligns product portfolios with emerging clinical needs and regulatory expectations. Investing in advanced topical delivery systems-such as microemulsions, nanostructured gels, and extended-release patches-will address growing patient demand for targeted anti-inflammatory therapy. Parallel efforts to strengthen supply chain resilience through diversified sourcing and near-shoring can safeguard against tariff volatility and raw material shortages.

Proactive engagement with regulatory authorities is essential to streamline approval pathways and secure fast-track designations for innovative formulations. Companies should also cultivate digital ecosystems that support remote patient monitoring, adherence tracking, and telehealth integration, thereby enhancing treatment outcomes and generating valuable real-world data. Finally, forging strategic alliances with academic institutions and contract research organizations will accelerate translational research and reduce time to market for breakthrough dermatological NSAID therapies.

Detailed overview of the research methodology including data sourcing analytical frameworks validation processes and quality assurance measures for market insights

This research integrates primary and secondary methodologies to ensure comprehensive market coverage and analytical rigor. Primary data was obtained through targeted interviews with key opinion leaders, including dermatologists, pharmacists, and industry executives, providing first-hand insights into clinical adoption trends, formulation challenges, and distribution dynamics. Secondary research encompassed industry publications, patent filings, regulatory dossiers, and company disclosures, which were systematically reviewed to validate market drivers, segmentation patterns, and competitive developments.

Quantitative data analysis employed triangulation techniques, cross-referencing supply-side inputs with demand-side intelligence to ensure consistency and accuracy. Quality assurance processes included peer reviews by sector experts and editorial audits to confirm clarity, coherence, and factual integrity. This robust research framework ensures that findings reflect the most current industry realities and provide a reliable foundation for strategic decision-making.

Concluding reflections on the critical drivers challenges and future opportunities for dermatological non-steroidal anti-inflammatory drug development and commercialization

The dermatological non-steroidal anti-inflammatory drug sector stands at an inflection point, propelled by formulation innovations, shifting regulatory paradigms, and evolving patient expectations. Key drivers such as the advent of high-efficacy topical systems, the expansion of digital health integration, and the imperative to navigate new tariff landscapes have collectively reshaped market dynamics. Challenges persist in harmonizing global regulatory requirements, maintaining supply chain agility, and differentiating product offerings amid intensifying competition.

Yet the horizon is marked by significant opportunities: personalized medicine approaches that leverage pharmacogenomic insights, next-generation delivery platforms that enhance tolerability and adherence, and strategic collaborations that bridge academic research with commercial development. As stakeholders embrace these prospects, the sector is poised to deliver impactful therapies that address both established and emerging inflammatory conditions, reinforcing the therapeutic value of dermatological NSAIDs in comprehensive patient care.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Route Of Administration
    • Oral
      • Capsule
      • Liquid
      • Tablet
    • Parenteral
      • Infusion
      • Injection
    • Topical
      • Cream
      • Gel
      • Ointment
      • Patch
      • Spray
  • Product Type
    • Injectable
    • Oral Capsule
    • Oral Liquid
    • Oral Tablet
    • Topical Cream
      • High Concentration
      • Low Concentration
      • Medium Concentration
    • Topical Gel
      • 1 To 2 Percent
      • < 1 Percent
      • >2 Percent
    • Topical Ointment
    • Topical Patch
    • Topical Spray
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End User
    • Clinics
    • Home Care Settings
    • Hospitals
  • Indication
    • Dermatological Conditions
    • Musculoskeletal Disorders
    • Osteoarthritis
    • Rheumatoid Arthritis
    • Soft Tissue Injuries
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Novartis AG
  • Bayer AG
  • Pfizer Inc.
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of nanoparticle-based topical NSAID formulations to enhance dermal penetration and minimize systemic absorption
5.2. Expansion of over-the-counter diclofenac gel offerings targeting consumer self-care for joint and muscle pain relief
5.3. Emergence of COX-2 selective topical inhibitors for targeted treatment of chronic inflammatory skin conditions
5.4. Integration of botanical and plant-derived non-steroidal anti-inflammatory extracts into prescription dermatology protocols
5.5. Strategic partnerships between pharmaceutical firms and dermatology clinics for clinical trials of novel topical NSAIDs
5.6. Regulatory trends imposing rigorous bioavailability and safety requirements for new topical NSAID approvals
5.7. Growth of personalized topical NSAID regimens supported by digital adherence monitoring and teledermatology services
5.8. Competitive pressure from generic topical NSAID manufacturers driving aggressive pricing and market access strategies
5.9. Development of multi-modal topical therapies combining NSAIDs with analgesic or antimicrobial agents in single formulations
5.10. Increasing investment in advanced transdermal delivery technologies to improve efficacy of non-steroidal dermatological treatments
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Dermatological Non-Steroidal Anti-Inflammatory Drugs Market, by Route Of Administration
8.1. Introduction
8.2. Oral
8.2.1. Capsule
8.2.2. Liquid
8.2.3. Tablet
8.3. Parenteral
8.3.1. Infusion
8.3.2. Injection
8.4. Topical
8.4.1. Cream
8.4.2. Gel
8.4.3. Ointment
8.4.4. Patch
8.4.5. Spray
9. Dermatological Non-Steroidal Anti-Inflammatory Drugs Market, by Product Type
9.1. Introduction
9.2. Injectable
9.3. Oral Capsule
9.4. Oral Liquid
9.5. Oral Tablet
9.6. Topical Cream
9.6.1. High Concentration
9.6.2. Low Concentration
9.6.3. Medium Concentration
9.7. Topical Gel
9.7.1. 1 To 2 Percent
9.7.2. < 1 Percent
9.7.3. >2 Percent
9.8. Topical Ointment
9.9. Topical Patch
9.10. Topical Spray
10. Dermatological Non-Steroidal Anti-Inflammatory Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Dermatological Non-Steroidal Anti-Inflammatory Drugs Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Care Settings
11.4. Hospitals
12. Dermatological Non-Steroidal Anti-Inflammatory Drugs Market, by Indication
12.1. Introduction
12.2. Dermatological Conditions
12.3. Musculoskeletal Disorders
12.4. Osteoarthritis
12.5. Rheumatoid Arthritis
12.6. Soft Tissue Injuries
13. Americas Dermatological Non-Steroidal Anti-Inflammatory Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Dermatological Non-Steroidal Anti-Inflammatory Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Dermatological Non-Steroidal Anti-Inflammatory Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis AG
16.3.2. Bayer AG
16.3.3. Pfizer Inc.
16.3.4. Johnson & Johnson
16.3.5. GlaxoSmithKline plc
16.3.6. Sanofi S.A.
16.3.7. Viatris Inc.
16.3.8. Teva Pharmaceutical Industries Ltd.
16.3.9. Sandoz International GmbH
16.3.10. Sun Pharmaceutical Industries Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET: RESEARCHAI
FIGURE 26. DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 27. DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET: RESEARCHCONTACTS
FIGURE 28. DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY LIQUID, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GEL, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GEL, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OINTMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OINTMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATCH, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATCH, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SPRAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SPRAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL LIQUID, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL LIQUID, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HIGH CONCENTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HIGH CONCENTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY LOW CONCENTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY LOW CONCENTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MEDIUM CONCENTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MEDIUM CONCENTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY 1 TO 2 PERCENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY 1 TO 2 PERCENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY < 1 PERCENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY < 1 PERCENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY >2 PERCENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY >2 PERCENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL OINTMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL OINTMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL PATCH, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL PATCH, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL SPRAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL SPRAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DERMATOLOGICAL CONDITIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DERMATOLOGICAL CONDITIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SOFT TISSUE INJURIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SOFT TISSUE INJURIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 151. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 152. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 153. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 154. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 155. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 156. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 157. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 158. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 159. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 160. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 161. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2024 (USD MILLION)
TABLE 162. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2025-2030 (USD MILLION)
TABLE 163. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2024 (USD MILLION)
TABLE 164. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2025-2030 (USD MILLION)
TABLE 165. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 170. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 171. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 172. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 173. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 174. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 175. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 176. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 177. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 178. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 179. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 180. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 181. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2024 (USD MILLION)
TABLE 182. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2025-2030 (USD MILLION)
TABLE 183. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2024 (USD MILLION)
TABLE 184. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2025-2030 (USD MILLION)
TABLE 185. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 186. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 187. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 188. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 189. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 190. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 230. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL CREAM, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL GEL, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILL

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Dermatological Non-Steroidal Anti-Inflammatory Drugs market report include:
  • Novartis AG
  • Bayer AG
  • Pfizer Inc.
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.

Related Topics

Related Reports

Non-steroidal Anti-inflammatory Drugs Market by Distribution Channel (Over The Counter, Prescription), Route Of Administration (Oral, Parenteral, Topical), Drug Class, Formulation, End User - Global Forecast 2025-2030 - Product Image

Non-steroidal Anti-inflammatory Drugs Market by Distribution Channel (Over The Counter, Prescription), Route Of Administration (Oral, Parenteral, Topical), Drug Class, Formulation, End User - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Non-steroidal Anti-inflammatory Drugs Market Size, Share & Trends Analysis Report By Disease Indication (Arthritis, Ophthalmic Diseases), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Non-steroidal Anti-inflammatory Drugs Market Size, Share & Trends Analysis Report By Disease Indication (Arthritis, Ophthalmic Diseases), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
Non-Steroidal Anti-inflammatory Drugs Market Report 2025 - Product Image

Non-Steroidal Anti-inflammatory Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Non-steroidal Anti-inflammatory Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Non-steroidal Anti-inflammatory Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 101 Pages
  • Global
From
Dental Anti-inflammatory Drug Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Dental Anti-inflammatory Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.